Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma
Conditions: Laryngeal Cancer; Hypopharynx Cancer; Laryngeal Neoplasms Intervention: Drug: chemotherapy TP regimen combined with Toripalimab Sponsor: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 6, 2021 Category: Research Source Type: clinical trials
A Single-arm, Multi-institutional, Phase 2 Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Condition: Squamous Cell Carcinoma of Larynx Interventions: Drug: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles; Radiation: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.; Drug: Consolidation i mmunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses. Sponsor: Latin American Cooperative Oncology Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
Condition: Squamous Cell Carcinoma of Larynx Interventions: Drug: carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles; Radiation: Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles.; Drug: Consolidation i mmunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses. Sponsor: Latin American Cooperative Oncology Group Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 29, 2021 Category: Research Source Type: clinical trials
